ABSTRACT. Congenital diaphragmatic hernia, a highly lethal condition, displays a t term the pulmonary biochemical and morphologic immaturity characteristic of premature delivery. \Ye hypothesized that antenatal glucocorticoid, now the standard treatment to prevent hyaline membrane disease in premature human beings, might correct the parameters of the pulmonary biochemical and morphologic immaturity in severe congenital diaphragmatic hernia.
ABSTRACT. Congenital diaphragmatic hernia, a highly lethal condition, displays a t term the pulmonary biochemical and morphologic immaturity characteristic of premature delivery. \Ye hypothesized that antenatal glucocorticoid, now the standard treatment to prevent hyaline membrane disease in premature human beings, might correct the parameters of the pulmonary biochemical and morphologic immaturity in severe congenital diaphragmatic hernia. A total of 112 fetal rats with or without nitrofen-induced congenital diaphragmatic hernias from 34 pregnancies were treated antenatally with either saline or desamethasone. Antenatal desamethasone increased the lung disaturated phosphatidylcholine content, reduced the lung glycogen concentration, reduced the saccular septal thickness, and increased the mean saccular size and volume fraction of saccules in the lungs of rats with large congenital diaphragmatic hernia in comparison with similar rats not so treated. All differences were statistically significant. Antenatal glucocorticoid therapy was efficacious in treating rats with nitrofen-induced congenital diaphragmatic hernia. This encouraging finding warrants further investigation in a large animal model with surgically created congenital diaphragmatic hernia. (Pediatr Res 35: 523-529, 1994) Abbreviations CDH, congenital diaphragmatic hernia non-CDII, noncongenital diaphragmatic hernia DSPC, disaturated phosphatidylcholine i.p., intraperitoneally RNase, ribonuclease ETI, endothelin 1 a smaller number of lamellar granules in type I1 pneumocytes: furthermore, the lecithin/sphingomyelin ratio was reduced and phosphatidylglycerol was absent in the amniotic fluid surrounding these otherwise normal full-term fetuses (9, 10) . although others have observed more normal ratios (I I, 12). George 1.f nl. (13) documented that lungs from 10 neonates dying of CDH (seven of them full term) were morphologically immature for their gestational age.
Antenatal maternal administration of glucocorticoids is an established therapy well known for diminishing the severity of hyaline membrane disease in premature babies (14, 15) . Its observed propitious effects on the lung include the accelerated appearance, accumulation, and secretion of surfactant (16) (17) (18) : a reduction of mesenchymal volume and narrowing of alveolar septal thickness (19) ; an increase in maximal lung volume (20) and compliance (21) ; and an increase of antioxidant enzyme activities in the fetal lung (22) , leading to decreased incidence, severity, and deaths resulting from neonatal respiratory distress syndrome associated with premature delivery (14, 15) .
We recently reported that neonatal rat lungs in the presence of large CDH created experimentally by maternal feeding of nitrofen (2,4-dichloro-4'-nitrodiphenyl ether) were biochemically and morphologically immature, as manifested by smaller, atelectatic lungs with diminished DSPC and a higher glycogen content (23) . We used this relatively inexpensive, short-gestation, small-animal model to study whether treatment of these animals with antenatal dexamethasone could significantly improve important parameters of pulmonary maturity. The experimental findings of this study indicate that the lungs in full-term human neonates with severe CDH, which are known to display similar biochemical and morphologic characteristics of prematurity, might respond to prenatal glucocorticoid therapy and thus improve their dismal outcome. Further studies in large non-nitrofen-treated animals will be needed to confirm these findings.
CDH occurs when the ~l e u r o~e r i t o n e a l s e~t u m fails to s e~a -
MATERIALS AND METHODS
rate the thoracic and abdbminai cavities: it ;esults in death 'for many affected infants despite the introduction of novel interventional therapies in conjunction with improved neonatal intensive care (1, 2). Death of infants with CDH is associated with profound pulmonary hypoplasia (3) (4) (5) and persistent pulmonary hypertension (6) . Convincing evidence has accumulated that the neonatal lung in the presence of lethal CDH is both biochemically and morphologically immature. Blackburn 1.t al. (7) in 1977 and Wigglesworth ct 01. (8) in 1981 showed that CDH lungs had significantly reduced lecithin (phosphatidylcholine) content and
The experimental design is outlined in Figure 1 . cavity were designated CDH rats, and pups without diaphragmatic hernias were designated non-CDH rats. All CDH rats wcre studied. Because non-CDH rats always outnumbered C D H rats, only a similar number of non-CDH rats from each pregnancy were randomly chosen for subsequent analysis. Pups with diaphragmatic hernias occupying less than 50% of the thoracic cavity wcre not analyzed so that a uniform degree of pulmonary hypoplasia among the analyzed C D H rats could be maintained.
Comparisons between treated and untreated rats were pcrformed with biochemical, morphologic, and molecular methods. Three dosages of dexamethasone were tested in the biochemical analyses. Because dexamethasone produced greater reduction of birth weight and lung weight in both the CDH and non-CDH rats, the lowest of the three dosages of dexamethasone that resulted in significant biochemical improvement but the least inhibition of somatic and pulmonary growth was used in the morphometrical and molecular experiments. Biochrr?~ical ar~a!,~scps. T o study biochemical differences, we gave animals three different dosages of dexamethasone (Gensia, (24) . The lower and higher doses were chosen empirically to study the dose-related response. The pups of five pregnant dams served as controls, with three dams uninjected and two injected with 0.15 m L (the volume of dexamethasone used in the treated groups) of normal saline i.p. on d 18.5, 19.5, and 20.5. O n d 2 1.5, 132 neonatal rats were delivered and their birth weights recorded. There were 30 CDH rats (24 leftsided and six right-sided); all were subsequently analyzed. Thirtyfive non-CDH rats were randomly selected from a pool of 92 for subsequent analysis. Ten other rats with only small CDH were excluded. Lungs from nine neonatal rats whose mother was fed olive oil only without nitrofen were also assayed for comparison to understand the effect of nitrofen on lung development. The number of rats used in each treatment group is shown in Figure  2A .
Each heart-lung block was removed from the chest, and the lungs were cleared of surrounding parenchyma, frozen in liquid nitrogen, and stored at -80°C. Lungs at the time of assay were weighed and homogenized (Polytron, Brinkmann Instruments,
Westbury. NY) on ice after adding 19 volumes of distilled water
to create a 20-fold dilution (assuming lung density of 1 g/mL). Six smaller lungs (three C D H and three non-CDH lungs) were diluted 30-fold. Lung homogenates were assayed for DSPC, protein, and glycogen content as previously reported (23) . Briefly, to assay for DSPC, we extracted lipid on 0.15 m L of the homogenate with a chloroform-methanol 2: 1 (vol/vol) mixture. After centrifugation, the supernatant was washed with 0.1 M potassium chloride solution according to Folch ct (11. (25) . After the upper phase was removed, the lower phase was evaporated to dryness with dry nitrogen gas. The lipid extract was reacted with osmium tetroxide, evaporated again, and the residue dissolved in chloroform-methanol 20: 1 (vol/vol). DSPC was isolated through an activated neutral alumina column after elution by chloroformmethanol-7M ammonium hydroxide 70:30:2 (vol/vol/vol) (26) . The amount of DSPC was determined by assaying the phosphorus content in the eluent by the method of Bartlett (27) . Glycogen was measured by the method of Lo ct (11. (28); 0.5 m L of the lung homogenate was digested with 30% potassium hydroxide saturated with sodium sulfate and precipitated with 95% ethanol. The glycogen precipitate was redissolved in water and the amount of glycogen determined by the phenol-sulfuric acid color reaction. Protein was determined by the method of Bradford (29) . ~\lorp/lor~lctrical anrr1jsi.s. For morphometrical analysis, pup lungs from six dexamethasone-treated (0.25 mg/kg i.p., d 18.5 and 19.5) and five untreated (saline-injected on the same days) dams were collected on d 2 1.5 by cesarean section. Before delivery from the uterus, each pup was given an i.p. injection of 6.5 mg pentobarbital to prevent subsequent insufllation by breathing air. After delivery, the trachea was cannulated and the lungs distended in sit11 with the chest open at 15-cm pressure with 10% formalin. Each trachea was then ligated to maintain the lungs in standardized inflation during fixation. Midcoronal paraffin sections (8 pm) stained with hematoxylin and eosin were studied stercologically with a Nikon Diaphot inverted microscope (Nikon, Garden City, NY) equipped with a 10x objective 526 SUEN ET .4L. with lung maturation (38) . Among the C D H rats, the mean lung at the dose of 0.25 mg/kg on d 18.5 and 19.5, only E T l gene glycogen concentrations were significantly decreased by antenatal expression (Fig. 7) showed a 1.8-fold increase in the non-CDH dexamethasone treatment at doses of 0.25 mg/kg i.p. for 3 d rats ( p < 0.001) and 2-fold increase in the C D H rats ( p C 0.001). and dexamethasone further reduced these two parameters in a births (39) , leading, in the United States with 4 million live dose-related manner in both the CDH and non-CDH rats (Fig. births, to approximately 1333 cases. The 60% mortality rate of
3).
CDH (40) would result in approximately 800 deaths a year, Mor~hologicall~, lungs in the untreated C D H rats have smaller which is 25% of deaths caused by congenital heart disease in the saccules and thicker saccular septal walls compared with un-1st y, or 1.3 times the deaths caused by leukemia from 0 to 14 y treated non-CDH rats, whereas antenatal dexamethasone en- (41, 42) . larged the pulmonary saccules and decreased the saccular septa1
Pulmonary hypoplasia, persistent pulmonary hypertension, wall thickness in the lungs of rats with large C D H (Fig. 4) . The and surfactant deficiency are pathognomonic of severe and lethal mean saccular volume of the untreated C D H rats (93 200 f CDH lungs. A similar pathophysiologic condition is found in 18 400 pm3), which was much smaller than that of the untrea!ed the lungs of premature infants with hyaline membrane disease.
non-CDH rats (275 000 + 17 000 pm', P < 0.00 11, was slgnlfi-Because antenatal glucocorticoid in premature babies has been cantly increased by dexamethasone treatment (148 000 + 17 300 proved to accelerate pulmonary maturity, thus reducing the elm', P = 0.03, Fig.   and B) . The volume fraction of saccules incidence and severity of hyaline membrane disease and leading in the lung of the untreated C D H rats (0.24 * 0.0 1). which was to improved survival, it is logical to consider the use of prenatal much smaller than that of the untreated non-CDH rats (0.4 * g~ucocorticoid therapy to accelerate pulmonary maturity in 0.001), was also increased by dexamethasone treatment (0.3 f CDH. We confirmed that nitrofen alone can suppress DSPC 0.02, p = 0.007, Fig. 5.4 and C) . content in lung and reduces the birth weight and lung weight. No significant differences were seen in the pulmonary SP-A. However, we have shown that antenatal glucocorticoid treatment SP-B, SP-C (Fig. 61, ETI (Fig. 7) , and endothelial nitric oxide elevated the DSPC content and reduced the glycogen concentrasynthase (Fig. 8 ) mRNA concentrations measured for whole-tion compared with nitrofen-treated animals who received no lung extracts between the untreated CDH and untreated non-dexamethasone and that DSPC improvement was more dramatic C D H rats fed nitrofen. After antenatal dexamethasone tF%mnCnt in the CDH lungs. Antenatal glucocorticoid treatment also reduced the saccular septal thickness and increased the saccular -dexamethasone did not increase surfactant-associated protein mRNA levels in either nitrofen-or nonnitrofen-treated controls differs from results observed by others who reported increases of SP-A, SP-B, and SP-C mRNA levels in immature non-CDH lungs of rats treated with dexamethasone (33, 34) . These differences may be the result of variations in dexamethasone dosage or timing of treatment. Further investigations by in sit11 hybridization and immunohistochemical localization may yield important cellular differences not appreciable by whole-lung extraction. Antenatal glucocorticoid, when used to treat premature babies, is less effective when given after 34 wk gestation or if the baby is delivered more than 7 d after therapy (14, 15) . Although most B babies with CDH are full term, we predict that their lungs will
Olive Oil
Nitrofen Fed respond to glucocorticoid because their lungs reflect the biochemical and morphologic patterns characteristic of prematurity (9, 10, 13) and fall within the well-known window of responsiveness to glucocorticoid therapy. Although glucocorticoid therapy in this study inhibited both somatic and pulmonary growth, long-term follow-up in other studies of both animals (43) and human beings (44. 45) treated for prematurity alone detected no subsequent deleterious effects on somatic, pulmonary, psychologic, or intellectual development. Other salutory effects included a decreased incidence of patent ductus arteriosus (46) , necrotizing enterocolitis (47) , and
intraventricular hemorrhage (48, 49) . and stimulation of lung Fig. 3 . Efl'ccts of antenatal dexamethasone on birth weight and lung antioxidant enzymes (22) . weight. Antenatal dexamethasone decreased birth weight (,.I) and lung Because antenatal glucocorticoid and postnatal surfactant reweight ( U ) in a dose-dependent manner in both the CDH ( . ) and non-placement therapy have additive beneficial effects in the respi-CDH rats (0). See Figure 2 ,t for number of animals represented by each ratory distress syndrome of prematurity (50) . the present study bar.
suggests that they may be similarly additive in neonates with IN) . The image was projected onto a Sony video monitor (Sony Corp., Tokyo, Japan). The randomized midcoronal sections of the right and left lungs were studied separately without knowledge of previous treatment. With right and left lungs counted separately, 18 lung sections from nine treated CDH rats were compared with 18 lung sections from nine untreated CDH rats and 16 lung sections from eight untreated non-CDH rats. Whenever possible, four fields on each lung section (randomly chosen from the superior, inferior, lateral, and medial aspects) were studied. In 1 1 of the 52 lung sections, only one to three fields were available for study because of pulmonary hypoplasia. A computer-generated grid containing 70 regularly spaced points, which had been previously calibrated with a 0.01-mm micrometer, was superimposed on the lung image on the video monitor. With the help of a cursor, the length of all intercepts (I,) through test points overlying saccule~were measured in a random direction, and the value of x/3.(lo3) was used as an unbiased estimate of the mean saccular volume sampled (30, 3 1 ). An average of 82 I,, measurements were made for each lung section. The ratio of points intercepting saccules to the points overlying the lung parenchyma is in turn a n objective estimate of the volume fraction of saccules in the lung (3 1). hlol~clrlar a11alj.sis. Gene expression of surfactant-associated proteins SP-A, SP-B, SP-C, ETI, and endothelial nitric oxide synthase was measured with RNA blot hybridization or a n RNase protection assay. Three dams were treated with 0.25 mg/ kg dexamethasone i.p. on d 18.5 and 19.5, and two dams were saline injected on the same days. From these pregnancies, six dexamethasone-treated and six untreated CDH rats were identified, and six treated and six untreated non-CDH rats were randomly chosen for analyses. Lungs harvested from these pups on d 2 1.5 ofgestation were immediately frozen in liquid nitrogen. RNA was extracted by the guanidine isothiocyanate/cesium chloride method (32) . For RNA blot hybridization, 10-pg RNA samples were fractionated on a formaldehyde-agarose gel and transferred to a nitrocellulose membrane. The membrane was scquentially hybridized with "P-labeled cDNA probes for SP-A, SP-B, and SP-C (33, 34) . The membrane was hybridized with 3'P-labeled I-kb PsfI restriction fragment of a cDNA encoding human glyceraldehyde-3-phosphate dehydrogenase to standardize the amount of RNA in each sample (35) . The quantity of hybridizing probe bound to the membrane was measured with a Betascope 603 blot analyzer (Betagen Corp., Waltham, MA). The SD of loading as determined by the glyceraldehyde-3-phosphate dehydrogenase mRNA level in individual samples of specimen was 2 1 %. SP-B mRNA was similarly studied in nonnitrofen (olive oil)-treated controls with (11 = 6) and without (11 = 6) glucocorticoid treatment for comparison.
For RNase protection assay, RNA samples were incubated with radiolabeled antisense cRNA probes derived from restriction fragments of the rat ETI gene (Bloch KD, unpublished observations) and o f a partial rat endothelial nitric oxide synthase cDNA (Bloch KD, unpublished observation). For preparation of a uniformly labeled antisense ETI cRNA probe, pGEM4-ETI (containing exon 2) was linearized with EcoRl and incubated with T 7 RNA polymerase in the presence of "P-uridine triphosphate. A partial endothelial nitric oxide synthase cDNA was amplified from rat lung RNA with degenerate oligonucleotides corresponding to amino acids 10 12 to 10 18 and I 1 14 to 1 120 of human endothelial nitric oxide synthase (36) . An approximately 250 bp BamHI/EcoRI restriction fragment was ligated into pGEM7zf. For preparation of a cRNA probe for rat endothelial nitric oxide synthase, the plasmid containing the partial cDNA was linearized with BartiHI and incubated with T 7 RNA polymerase. A radiolabeled antisense cRNA probe for human y-actin (37) was added to each hybridization to confirm that equal concentrations of RNA were hybridized. RNA fragments protected from RNase were fractionated on a 6% urea-polyacrylamide gel. Hybridization of ETI RNA probe with ETI mRNA protected a predominantly 141-nucleotide radiolabeled fragment. Rat 7-actin mRNA protected an approximately 80-nucleotide fragment of human y-actin probe. The quantity of protected probe was measured with the Betascope 603 blot analyzer. The S D of loading as determined by the y-actin mRNA levels for the endothelin and the endothelial nitric oxide synthase experiments were 43% and 24%, respectively.
Results were expressed as mean a SEM. Comparisons were analyzed statistically by analysis of variance, independent r test, and post lloc testing: p < 0.05 was statistically significant.
RESULTS
The DSPC content, which normally rises with maturity, was reduced significantly in the nitrofen non-CDH rats (64.6 & 2.7 pg/mg protein) compared with the olive oil rats (90. (Fig. 2A) . A similar dexamethasone response was observed among the nitrofen non-CDH rats.
Lung glycogen mean concentrations normally fall coincident Representative results of RNase protection assay showing no change in pulmonary endothelin 1 mRNA level between untreated CDH and non-CDH rats. There was, however, a 1.8-fold increase in the non-CDH rats ( p < 0.001) and 2-fold increase in the CDH rats ( p < 0.001) after antenatal dexamethasone treatment. NS, normal saline. prenatally diagnosed CDH. Antenatal ultrasonography can visualize these defects, and cases exhibiting criteria indicative of a near 100% mortality rate can be predicted with accuracy (I, 2); therefore, treatment of these babies with an established agent such as antenatal glucocorticoid should be considered as a therapeutic option after confirmation of the present observations in larger animal models with surgically created C D H without the use of nitrofen. When appropriate, antenatal glucocorticoid treatment should be compared or combined with surfactant replacement therapy (5 I), extracorporeal membrane oxygenation (52), or nitric oxide inhalation therapy (53) in the treatment of babies with severe CDH. 
